These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25703583)

  • 21. Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib.
    Sandler A
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):17-22. PubMed ID: 14682119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Off-label use of bevacizumab: advanced adenocarcinoma of the pancreas.
    Technol Eval Cent Assess Program Exec Summ; 2009 Oct; 24(4):1-3. PubMed ID: 20183930
    [No Abstract]   [Full Text] [Related]  

  • 24. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of bevacizumab in patients with metastatic breast cancer.
    Hamilton EP; Blackwell KL
    Oncology; 2011; 80(5-6):314-25. PubMed ID: 21778772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Shipley DL; Reeves J; Arrowsmith ER; Barnes EK; Waterhouse DM
    Clin Genitourin Cancer; 2013 Sep; 11(3):283-289.e1. PubMed ID: 23684421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
    Uronis HE; Jia J; Bendell JC; Howard L; Ready NA; Lee PH; Starr MD; Dellinger A; Pang H; Nixon AB; Hurwitz HI
    Cancer Chemother Pharmacol; 2015 Feb; 75(2):343-52. PubMed ID: 25527204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
    Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
    Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO.
    Pivot X; Schneeweiss A; Verma S; Thomssen C; Passos-Coelho JL; Benedetti G; Ciruelos E; von Moos R; Chang HT; Duenne AA; Miles DW
    Eur J Cancer; 2011 Nov; 47(16):2387-95. PubMed ID: 21757334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers.
    Nemunaitis J; Hochster HS; Lustgarten S; Rhodes R; Ebbinghaus S; Turner CD; Dodion PF; Mita MM
    Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):336-42. PubMed ID: 23615181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.
    Minion LE; Bai J; Monk BJ; Robin Keller L; Ramez EN; Forde GK; Chan JK; Tewari KS
    Gynecol Oncol; 2015 Jun; 137(3):490-6. PubMed ID: 25766118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Administration-limiting factor of bevacizumab for patient with metastatic colorectal cancer].
    Kawazoe Y; Hatake K; Suenaga M; Mizunuma N
    Nihon Rinsho; 2011 Apr; 69 Suppl 3():472-6. PubMed ID: 22214006
    [No Abstract]   [Full Text] [Related]  

  • 34. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies.
    Zondor SD; Medina PJ
    Ann Pharmacother; 2004; 38(7-8):1258-64. PubMed ID: 15187215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.
    Klamerus JF; Brahmer JR
    Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S51-6. PubMed ID: 21884999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study.
    Lutrino SE; Bergamo F; Schirripa M; Rosati G; Avallone A; Giampieri R; Cordio S; Berretta M; Llimpe FR; Pisa FE; Lonardi S; Loupakis F; Fasola G; Aprile G
    Anticancer Res; 2015 Apr; 35(4):2391-9. PubMed ID: 25862905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.
    Barnett JC; Alvarez Secord A; Cohn DE; Leath CA; Myers ER; Havrilesky LJ
    Cancer; 2013 Oct; 119(20):3653-61. PubMed ID: 23921967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research progress on the mechanisms of combined bevacizumab and radiotherapy.
    Zhuang HQ; Yuan ZY; Wang P
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):129-34. PubMed ID: 24032532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics of bevacizumab in cancer patients with external validation.
    Han K; Peyret T; Marchand M; Quartino A; Gosselin NH; Girish S; Allison DE; Jin J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):341-51. PubMed ID: 27329360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of the American ODAC statement on Austrian bevacizumab prescribing practice for metastatic breast cancer.
    Preusser M; Fülöp G; Berghoff AS; Heinzl H; Steger GG; Greil R; Zielinski CC; Bartsch R
    Oncologist; 2012; 17(7):e13-7. PubMed ID: 22744818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.